TrialDiabetes, obesity & metabolism2023

Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.

Rosalie A Scholtes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.